Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Brigitte Lacroix"'
Autor:
Laurent Beghin, Nathalie Duhal, Philippe Poulain, Philippe Hauw, Brigitte Lacroix, Jean-Michel Lecerf, Jean-Paul Bonte, Jean-Charles Fruchart, Gérald Luc
Publikováno v:
Journal of Lipid Research, Vol 41, Iss 7, Pp 1172-1176 (2000)
The measurement of apolipoprotein B (apoB) in purified lipoproteins by immunological assays is subject to criticism because of denatured epitopes or immunoreactivity differences between purified lipoproteins and standard. Chemical methods have theref
Externí odkaz:
https://doaj.org/article/8db1b4bf80ac40d49f72cfb86320fb2c
Autor:
Joël Mercier, Koen Van Laere, Nathalie Mertens, Michel Koole, Kim Serdons, Brigitte Lacroix, David Sciberras, Ralph Paul Maguire
Publikováno v:
Molecular Imaging and Biology. 22:444-452
The aim of this study was to evaluate different non-invasive methods for generating (R)-1-((3-([11C]methyl)pyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one) ([11C]UCB-J) parametric maps using white matter (centrum semi-ovale–SO) as re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a4366ca0c6f0a9452f02b62137c4102
https://doi.org/10.1007/s11307-019-01387-6
https://doi.org/10.1007/s11307-019-01387-6
Autor:
Jonas Hannestad, Bernhard J. Steinhoff, Massimiliano Germani, Koen Van Laere, Konrad J. Werhahn, Christian Otoul, David Sciberras, Manuel Toledo, Christian Brandt, Rafal M. Kaminski, Marian Majoie, Steven DeBruyn, Pierandrea Muglia, Wim Van Paesschen, Brigitte Lacroix, Elizabeth Webster
Publikováno v:
Brain Communications
Brain Communications, 2(2):183. Oxford University Press
Brain Communications, 2(2):183. Oxford University Press
Therapeutic options for patients with treatment-resistant epilepsy represent an important unmet need. Addressing this unmet need was the main factor driving the drug discovery program that led to the synthesis of padsevonil, a first-in-class antiepil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f729a1db940c38ae2356fe351d63866
https://doi.org/10.1093/braincomms/fcaa183
https://doi.org/10.1093/braincomms/fcaa183
Autor:
Joël Mercier, Kim Serdons, Brigitte Lacroix, Paul Maguire, David Sciberras, Martijn Devrome, Koen Van Laere, Nathalie Mertens, June van Aalst, Michel Koole
PURPOSE: A [11C]UCB-J blocking study was performed in healthy volunteers to validate simplified, non-invasive measures for quantifying presynaptic SV2A expression using subcortical white matter as reference tissue. METHODS: Ninety minutes dynamic [11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::612de3cfddfaf94021b3df8259a8fdc9
https://lirias.kuleuven.be/handle/123456789/628111
https://lirias.kuleuven.be/handle/123456789/628111
Autor:
Michel, Koole, June, van Aalst, Martijn, Devrome, Nathalie, Mertens, Kim, Serdons, Brigitte, Lacroix, Joel, Mercier, David, Sciberras, Paul, Maguire, Koen, Van Laere
Publikováno v:
European journal of nuclear medicine and molecular imaging. 46(2)
A [Ninety minutes dynamic [After pretreatment, regional VThis [
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::61ace544dcf4a2e285d2d5428d70386f
https://pubmed.ncbi.nlm.nih.gov/30121895
https://pubmed.ncbi.nlm.nih.gov/30121895
Publikováno v:
Drug Metabolism and Pharmacokinetics. 29:61-68
Levetiracetam [E Keppra(®)] is a second generation antiepileptic drug for different types of epilepsy in adults and children ≥1 month. The objective is to develop a population pharmacokinetic model to describe the pharmacokinetics of levetiracetam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::057d995e15af67eaa1b39b773d7cb62a
https://doi.org/10.2133/dmpk.dmpk-13-rg-045
https://doi.org/10.2133/dmpk.dmpk-13-rg-045
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 39:177-193
The aim of this study is to present and evaluate an alternative sequential method to perform population pharmacokinetic-pharmacodynamic (PKPD) analysis. Simultaneous PKPD analysis (SIM) is generally considered the reference method but may be computat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dfe4b3a1e64ac1cf9e5efcd31dae437
https://doi.org/10.1007/s10928-012-9240-x
https://doi.org/10.1007/s10928-012-9240-x
Autor:
Maria-Laura Sargentini-Maier, Mats O. Karlsson, Lena E. Friberg, Armel Stockis, M R Lovern, Brigitte Lacroix
Publikováno v:
Clinical Pharmacology & Therapeutics. 86:387-395
The American College of Rheumatology (ACR) 20% preliminary definition of improvement in rheumatoid arthritis (RA) (ACR20) is widely used in clinical trials to assess response to treatment. The objectives of this analysis were to develop an exposure-r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f7f8413f457ad07ee2646fd3b6f260d
https://doi.org/10.1038/clpt.2009.136
https://doi.org/10.1038/clpt.2009.136
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
The Markovian approach has been proposed to model American College of Rheumatology's (ACR) response (ACR20, ACR50, or ACR70) reported in rheumatoid arthritis clinical trials to account for the dependency of the scores over time. However, dichotomizin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e992db16b496c42f3a8c2abfd6f3110d
https://pubmed.ncbi.nlm.nih.gov/25353186
https://pubmed.ncbi.nlm.nih.gov/25353186
Autor:
Philippe Jacqmin, Brigitte Lacroix, Armel Stockis, Nathalie Toublanc, Maria Laura Sargentini-Maier
Publikováno v:
Clinical pharmacokinetics. 47(5)
To characterize levetiracetam pharmacokinetics, identify significant covariate relationships and identify doses in children that achieve blood concentrations similar to those observed in adults.Nonlinear mixed-effects modelling was used to analyse po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be1d0b3949f29e9a90adb37db02b356a
https://pubmed.ncbi.nlm.nih.gov/18399714
https://pubmed.ncbi.nlm.nih.gov/18399714